SEC Form 4 · accession 0001203311-17-000052
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Aug 17, 2017
Accepted (ET)
Aug 18, 2017 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Aug 17, 2017 | A | 67,200 | $0.00 | A | 703,635 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F4 | $46.37 | Aug 17, 2017 | A | 2,156 | A | — | Aug 17, 2027 | Common Stock | 2,156 | 2,156 | D |
| Non-Qualified Stock Option (right to buy)F4 | $46.37 | Aug 17, 2017 | A | 165,844 | A | — | Aug 17, 2027 | Common Stock | 165,844 | 165,844 | D |
Explanation of responses
- F1These shares represent restricted stock units and will be settled in common stock upon vesting.
- F2Restricted stock units shall vest in full three (3) years from grant date.
- F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F4Shares shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years form grant date.